AQEMIA is a next-generation pharmatech company with a unique-in-the-world technology combining quantum-inspired physics and machine learning. Their mission is to scale the drug discovery process by leveraging their innovative algorithms and generative AI to design fast innovative drug candidates for critical diseases.

Maximilien Levesque

Emmanuelle Rolland-Martiano

AQEMIA

Aqemia is a pharmatech company using quantum physics and artificial intelligence to transform the drug discovery process. With a unique proprietary technology that preclude the use of experimental data, our pipeline scales the drug discovery process at an unprecedented pace, generating an exhaustive number of new drug candidates.
We are hiring! Check our career website: https://jobs.lever.co/aqemia.com

Blog Posts on: https://medium.com/aqemia

Elaia

Bpifrance

Eurazeo

AQEMIA and Sanofi embark on a groundbreaking $140 million drug discovery collaboration!

This new collaboration aims at scaling up our ongoing R&D work and successes with Sanofi to several targets in various therapeutic areas.

We will leverage Aqemia's unique GenAI x Deep physics to invent new drugs  faster together with Sanofi's experts.

This marks a turning point in Aqemia's history since its inception 4 years ago, and we can't wait to continue pushing boundaries of drug discovery with our amazing team and partners.

Check out for more details in the press release below 👇 


#drugdiscovery #pharma #genAI #quantumphysics #biotech #ai 

cc Laurent Schio Jean Philippe Rameau Houman Ashrafian Frank Nestle Dr. Thomas Licher Brian Bronk Audrey Derveloy Jacques Volckmann Nicolas Canouï Jean-Charles Bodet

Our co-founders Maximilien Levesque and Emmanuelle Martiano are at the JPMorgan 2024 conference in SF. Reach-out to them!

#jpm2024 #jpmorgan #jpm #pharma #biotech #techbio

Thanks to Walden Catalyst Ventures, Lakestar and Dealroom.co for featuring AQEMIA in the 3rd report on European Deep Tech, launched at Slush 🚀

If you're eager to explore the dynamic landscape of European deep tech, don't miss out on this report! Dive in for insights and inspiration through the link below. 👇😉 
https://lnkd.in/erArht7R

cc Maximilien Levesque Emmanuelle Martiano Rolland Nicolas Autret Lukas Leitner Mistral AI Google DeepMind Exscientia DNA Script

Our team is thrilled to welcome you at the Forum Horizon Chimie 🧪

Calling all students and others with a passion for #drugdiscovery and a drive to make a difference 👉 We have over 30 positions available for individuals who are eager to contribute to the next generation of life-changing drugs (link in the 1st comment). 

Thanks to Chimie ParisTech - PSL, ESPCI Paris - PSL, ENSIC et ECPM Ecole européenne de chimie polymères et matériaux de Strasbourg for your warm welcome! 

Due to our fantastic team, AQEMIA is well represented on this day! Piermichele Kobauri Nicolas George Salete Baptista Alessio Prunotto 

#jobopportunities #forum #drug #AI #deeptech 

Maximilien Levesque Emmanuelle Martiano Rolland Marion Birolini

Thrilled to have had the opportunity to share our perspective at #BIG! 

A heartfelt thank you to Bpifrance for allowing our cofounders, Maximilien Levesque and Emmanuelle Martiano Rolland, to showcase our vision of #drug #discovery and #entrepreneurship through several enlightening talks. 

A big salute to the teams of Bpifrance and Nicolas Dufourcq for orchestrating this impressive business event, the largest of its kind in Europe! 

Even prouder to have moderated a debate with Laurent Schio, Head of Integrated Drug Discovery at Sanofi, and walk on the same stage as such exceptionally inspiring people: Paul-François Fournier (Bpifrance), Xavier Niel, Alain Aspect (2022 Nobel Prize in Physics), Bruno Le Maire, David Louapre (Ubisoft), Xavier Dorison, Gilles Moreau (Verkor), Xavier Fontanet (Essilor), Sophie Brac de la Perrière (Healshape) 🌟

cc Rosalie MAURISSE Catherine Borg Capra Sophie Rémont Laurent Higueret Maïlys Ferrere

Another proud moment for AQEMIA to be named among the top 11 #drug #discovery startups to watch, as recognized by #VCs 👀
 
A special thanks to Alexandre Momeni from General Catalyst for this spotlight. We extend our heartfelt thanks to Sifted for the recognition!

Explore the article 🔎 https://lnkd.in/eaAwX7Cc   

#drugdiscovery #AI #VCs 

cc Maximilien Levesque Emmanuelle Martiano Rolland Nicolas Canoui Marion Birolini

🚀 Explore exciting opportunities at AQEMIA's booth during the X-Forum! 

Join us to learn about our fantastic team and groundbreaking work in #DrugDiscovery. Let's shape the future together! 

Discover a multitude of #JobOpportunities that could be the launchpad of your career! Link in the 1st comment 👇 

Maximilien Levesque Emmanuelle Martiano Rolland Nicolas Canoui Aloÿs Augustin Louise Lecointre Khaoula Belahsen Toby Johnstone École Polytechnique

Exciting announcement: AQEMIA has been chosen as one of the seven pioneering AI/ML for Life Sciences companies revolutionizing drug discovery and development.

We're thrilled to join six other leading AI/ML innovators recognized in the prestigious Clarivate Companies to Watch report. We're truly privileged to stand as ambassadors for France and Europe, but also share this stage with esteemed counterparts from the USA, Israel, South Korea, and the UK.

Congrats to the other companies Auransa Enveda Biosciences PharOS Ltd Quris AI Relation Therapeutics SandboxAQ! 

Find the full press release in the article below 👇 

cc Emmanuelle Martiano Rolland Maximilien Levesque Nicolas Canoui Marion Birolini Antoine Zins (Eurazeo) Laurent Higueret (Bpifrance) Sofia Dahoune (Elaia)

AQEMIA is proud to be laureate of La French Tech 2030. 🚀🚀🚀  


#france2030 #innovation #deeptech #drugdiscovery #growth #tech #startups

cc Clara Chappaz Lise ALTER Jean-Noël Barrot Ecole normale supérieure - PSL Research University CNRS #france

We are happy to see you tonight at 19h at PariSanté Campus for the 41st edition of the Meetup Paris Data Ladies 🚀 🚀 🚀 
You will have the opportunity to meet Khaoula Belahsen, our Hit Identification Team Leader, who will speak about Active Learning for virtual screening of molecules in drug discovery 💊  

You can access virtually the session through this link: https://lnkd.in/exVF_kWC
#drugdiscovery #paris #sciences

Metric
Company Name	AQEMIA
Symbol
MSH ID	COM:AQEMIA
Market	PRIVATE
Sector	Healthcare
Industry	Pharmaceuticals
Country	FR
Stage	Series A
Employee Count	50
Website	aqemia.com
LinkedIn	aqemia
Founders

Metric
Market Cap	99M
Enterprise Value
Monthly Web Traffic	2.77K
Web Traffic Growth	1.81
Valuation
Raised Capital	32.53M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:AQEMIA

AQEMIA

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue